Benjamin Tan
About
Benjamin Tan is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Benjamin Tan has authored 163 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Oncology, 53 papers in Surgery and 51 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Benjamin Tan's work include Colorectal Cancer Treatments and Studies (47 papers), Pancreatic and Hepatic Oncology Research (41 papers) and Hepatocellular Carcinoma Treatment and Prognosis (24 papers). Benjamin Tan is often cited by papers focused on Colorectal Cancer Treatments and Studies (47 papers), Pancreatic and Hepatic Oncology Research (41 papers) and Hepatocellular Carcinoma Treatment and Prognosis (24 papers). Benjamin Tan collaborates with scholars based in United States, Canada and France. Benjamin Tan's co-authors include Lee Ratner, David Piwnica‐Worms, Joel Picus, Charles D. Blanke, Martin E. Blackstein, Murray F. Brennan, George D. Demetri, Shreyaskumar Patel, Karla V. Ballman and Robert G. Maki and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.
In The Last Decade
Benjamin Tan
153 papers receiving 4.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Benjamin Tan United States | 33 | 2.9k | 1.9k | 1.6k | 886 | 829 | 163 | 5.0k | ||
| Tomoyuki Kato Japan | 43 | 2.6k 0.9× | 2.0k 1.1× | 2.3k 1.4× | 683 0.8× | 1.1k 1.3× | 211 | 5.5k | ||
| John F. Gibbs United States | 39 | 2.1k 0.7× | 1.6k 0.8× | 1.9k 1.2× | 514 0.6× | 705 0.9× | 150 | 4.7k | ||
| Tomohiro Nishina Japan | 35 | 2.7k 0.9× | 2.2k 1.2× | 1.1k 0.7× | 662 0.7× | 665 0.8× | 231 | 4.3k | ||
| Roderich E. Schwarz United States | 42 | 2.2k 0.8× | 2.4k 1.3× | 2.0k 1.2× | 573 0.6× | 1.2k 1.4× | 184 | 5.7k | ||
| Thomas Aparicio France | 40 | 3.6k 1.2× | 2.1k 1.1× | 1.8k 1.1× | 1.1k 1.3× | 716 0.9× | 254 | 6.5k | ||
| Young Suk Park South Korea | 41 | 4.0k 1.4× | 2.3k 1.2× | 1.9k 1.2× | 436 0.5× | 1.3k 1.6× | 227 | 6.3k | ||
| Naureen Starling United Kingdom | 29 | 3.8k 1.3× | 2.7k 1.4× | 1.6k 1.0× | 763 0.9× | 1.2k 1.4× | 171 | 6.2k | ||
| Sook Ryun Park South Korea | 31 | 1.9k 0.7× | 3.1k 1.7× | 1.6k 1.0× | 1.2k 1.4× | 839 1.0× | 153 | 4.8k | ||
| Masayuki Ohue Japan | 38 | 3.0k 1.0× | 1.9k 1.0× | 2.8k 1.7× | 310 0.3× | 1.0k 1.3× | 317 | 5.8k | ||
| Gennaro Galizia Italy | 43 | 2.8k 1.0× | 1.9k 1.0× | 1.3k 0.8× | 350 0.4× | 1.2k 1.4× | 140 | 5.2k |
Countries citing papers authored by Benjamin Tan
Since
Specialization
Citations
This map shows the geographic impact of Benjamin Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Tan more than expected).
Fields of papers citing papers by Benjamin Tan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Benjamin Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Tan. The network helps show where Benjamin Tan may publish in the future.
Co-authorship network of co-authors of Benjamin Tan
This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Tan. A scholar is included among the top collaborators of Benjamin Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Tan. Benjamin Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Raghav, Kanwal, Katherine A. Guthrie, Benjamin Tan, et al.. (2025). Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. Journal of Clinical Oncology. 43(11). 1348–1357.
2.
Xu, Sheng, Ziwei Hu, Weihao Zheng, et al.. (2025). GSH-responsive Pt-based nanomotor with improved doxorubicin delivery for synergistic osteosarcoma chemotherapy. Acta Biomaterialia. 195. 390–405.
3.
Grierson, Patrick, Rama Suresh, Andrea Wang‐Gillam, et al.. (2025). Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Clinical Cancer Research. 31(17). 3644–3651.
4.
Malone, C., Darren R. Cullinan, Maria B. Majella Doyle, et al.. (2025). Ultra-selective radiation segmentectomy for early-stage hepatocellular carcinoma. JHEP Reports. 8(1). 101636–101636.
5.
Grierson, Patrick, Rama Suresh, Benjamin Tan, et al.. (2023). A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy. Clinical Cancer Research. 29(23). 4733–4739.
6.
Grierson, Patrick, Rama Suresh, Benjamin Tan, et al.. (2023). A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer whose disease progressed on gemcitabine-based therapy.. Journal of Clinical Oncology. 41(16_suppl). e16263–e16263.
7.
Kasi, Pashtoon Murtaza, et al.. (2023). Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with advanced colorectal cancer (aCRC): A real-world (RW) analysis.. Journal of Clinical Oncology. 41(4_suppl). 246–246.
8.
He, Aiwu Ruth, Benjamin Tan, Thatthan Suksombooncharoen, et al.. (2023). Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.. Journal of Clinical Oncology. 41(4_suppl). 550–550.
9.
Aliabadi‐Wahle, Shaghayegh, et al.. (2023). Transgender Males on Gender-Affirming Hormone Therapy and Hepatobiliary Neoplasms: A Systematic Review. Endocrine Practice. 29(10). 822–829.
10.
Grierson, Patrick, Benjamin Tan, Katrina S. Pedersen, et al.. (2022). Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. The Oncologist. 28(2). e115–e123.
11.
Lim, Kian‐Huat, Mateusz Opyrchal, Ningying Wu, et al.. (2021). Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. European Journal of Cancer. 154. 102–110.
12.
Sanjeevaiah, Aravind, Rama Suresh, Rutika Mehta, et al.. (2020). P-131 Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial. Annals of Oncology. 31. S132–S132.
13.
Yau, Thomas, Philippe Merle, Lorenza Rimassa, et al.. (2018). Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). Annals of Oncology. 29. ix46–ix46.
14.
Harding, James J., Joseph P. Erinjeri, Benjamin Tan, et al.. (2018). A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 36(15_suppl). TPS4146–TPS4146.
15.
Liu, Jingxia, David C. Linehan, Marcus Tan, et al.. (2017). Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. HPB. 19(5). 449–457.
16.
Markovina, Stephanie, Amit Roy, Sonya Aggarwal, et al.. (2017). Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. International Journal of Radiation Oncology*Biology*Physics. 99(2). 417–426.
17.
Kim, Richard D., Philip M. Arlen, Kwong Y. Tsang, et al.. (2017). Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial.. Journal of Clinical Oncology. 35(15_suppl). 3081–3081.
18.
Brauer, David G., Matthew S. Strand, Dominic E. Sanford, et al.. (2016). Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. HPB. 19(2). 133–139.
19.
Tan, Benjamin & Howard L. McLeod. (2005). Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Seminars in Oncology. 32(1). 113–119.
20.
Tan, Benjamin, David Piwnica‐Worms, & Lee Ratner. (2000). Multidrug resistance transporters and modulation. Current Opinion in Oncology. 12(5). 450–458.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tomoyuki Kato Breakdown of academic impact, for papers by John F. Gibbs Breakdown of academic impact, for papers by Tomohiro Nishina Breakdown of academic impact, for papers by Roderich E. Schwarz Breakdown of academic impact, for papers by Thomas Aparicio Breakdown of academic impact, for papers by Young Suk Park Breakdown of academic impact, for papers by Naureen Starling Breakdown of academic impact, for papers by Sook Ryun Park Breakdown of academic impact, for papers by Masayuki Ohue Breakdown of academic impact, for papers by Gennaro Galizia